Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

ional product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the QNEXA End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL for QNEXA; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based o
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the ... a company overview at J.P. Morgan,s 29th Annual Healthcare Conference ... the Westin St. Francis Hotel in San Francisco, CA. ... be available on the "Investors & Media" section of the ...
... Mass., Jan. 6, 2011 Saints Medical Center, a ... is pleased to announce it has entered into a ... ZOLL ) of Chelmsford, Mass., a leader in comprehensive ... Saints-based EMS service working with ZOLL to collaborate on ...
Cached Medicine Technology:Isis Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement 2Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement 3
(Date:12/21/2014)... 21, 2014 Hundreds of Byetta ... claims involving a class of Type 2 diabetes ... forward in a federal multidistrict litigation now underway ... Bernstein Liebhard LLP reports. According to an Order ... data cut-off date of February 27, 2014 for ...
(Date:12/21/2014)... Mi (PRWEB) December 21, 2014 AlignLife ... child in need while at the same time helping people ... is a non-profit community-based organization committed to serving those persons ... meet their needs to improve the quality of life. Dr. ... make an impact in the local community and he knew ...
(Date:12/21/2014)... OR (PRWEB) December 21, 2014 ... some of the issues and systemic barriers for disabled ... World Paratriathlon Champion. Scheidies has a condition called juvenile ... time. He describes how he adapted his athletic ambitions ... use his success in triathlon to pioneer the way ...
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
(Date:12/20/2014)... 21, 2014 MissyDress, a distinguished special ... prom lovers. The business has drastically cut prices to ... to everyone until Jan. 30, 2015. Many of the ... dresses, V-neck dresses, lace dresses, and more. , A ... there every day. Whether A-line princess prom dresses or ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... , , , ... a major expansion to its product offering with the ... (MAPS) and the integration of the ClearPoint Security Performance ... solution - The ClearPoint Unified Security Performance and Compliance ...
... , , ... Oz Show," a high octane, multi-topic hour-long series hosted by trusted ... premieres in syndication today (check local listings). Episodes airing ... Team Oz" guest contributors, fashion and style expert Tim Gunn ("Project ...
... , MealsMatter.org Offers Delicious Ways to Keep the ... Sept. 14 As flu season grips the nation with heightened awareness ... method getting left out in the cold. , , ... groups throughout the year, but it,s particularly significant during flu season," said ...
... ... the results of the largest study ever performed of tubal reversal surgery, ... is more successful than IVF for couples wanting more children after a ... of the tubal reversal patients had reported pregnancies. "A simple one-hour outpatient ...
... , , , PITTSBURGH, Sept. ... Inc. is prototyping an innovative stroke treatment device designed to speed ... , , Michele Migliuolo, NeuroInterventions President ... a presentation at the 3 Rivers Venture Fair in Pittsburgh on ...
... works in different way than standard medicines , SUNDAY, ... people whose high blood pressure cannot be controlled by ... researchers report. , Substantial reductions in blood pressure were ... people who were still hypertensive despite trying three or ...
Cached Medicine News:Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 2Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 3Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 4Health News:'The Dr. Oz Show' Premieres Today Nationwide 2Health News:'The Dr. Oz Show' Premieres Today Nationwide 3Health News:'The Dr. Oz Show' Premieres Today Nationwide 4Health News:'The Dr. Oz Show' Premieres Today Nationwide 5Health News:Protect Your Family With Flu-Fighting Foods 2Health News:Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation 2Health News:Rapid-response Technology from NeuroInterventions, Inc. Aims to Quickly Restore Brain's Blood Flow After a Stroke 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
8 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.6 inches....
Medicine Products: